Achrafieh, Beirut , Lebanon
Dubai, Damac executive heights, office 1901

MEFS Exchange course & Symposium

MEFS Exchange course - ESHRE2019

Pre-treatment strategies in assisted reproductive technology: Does the management of pre-existing gynecologic and endocrine conditions improve the outcome of ART cycles?

Precongress Course 16

Sunday 23 June 2019

Course type

Advanced and Basic

Course co-ordinator(s)
Johnny Awwad (Lebanon) and Mohammad Aboulghar (Egypt)

Course description
Beyond technological advances, the success of Assisted Reproductive Technology also depends on the personal characteristics of the patient undergoing the procedure. Some of these characteristics may represent pre-existing benign gynecological conditions, e.g. endometriosis, fibroids, adenomyosis, hydrosalpinx, uterine adhesions; or endocrine disorders, e.g. hypothyroidism, hyperprolactinemia and PCOS. The decision to address these conditions prior to the IVF/ICSI treatment cycle may often lead to unnecessary and potentially harmful interventions, and should therefore be based on established scientific evidence.
This Precongress Course discusses some of these gynecological/endocrine conditions, their impact on the success of IVF/ICSI and the efficacy of proposed pre-treament strategies in view of emerging scientific evidence.

Target audience

  • Reproductive Endocrinologists and Fertility Specialists
  • Biologists involved in Assisted Reproductive Technologies
  • Policy Regulators and Representatives of Third Party Payers

Educational needs and expected outcomes 

At the completion of this pre-congress course, participants should be able to:

  • Describe the mechanisms by which specific gynecologic and endocrine conditions affect the outcome of IVF/ICSI cycles
  • Appraise the literature regarding common practices resulting in potential harm and no proven benefit
  • Understand the cost effectiveness of surgical and medical inerventions proposed as IVF/ICSI pre-treatments to improve outcome
  • Develop an evidence-based decision tree on when and if these interventions are efficacious and medically indicated



Sunday 23 June 2019
Chair: Johnny Awwad, Lebanon 
09:00 - 09:30   Pre-IVF treatment of endometriosis: What, when and for how long?
                       Johnny Awwad, Lebanon 
09:30 - 09:45   Discussion 
09:45 - 10:15   Pre-IVF treatment of uterine fibroids: When does intervention become beneficial?
                        Mohamed Aboulghar, Egypt
 10:15 - 10:30  Discussion 
10:30 - 11:00  Coffee break 
Chair: Michel Abou Abdallah, Lebanon 
11:00 - 11:30   Pre-IVF treatment of uterine adenomyosis: Is intervention useful at all?
                        Togas Tulandi, Canada 
11:30 - 11:45   Discussion 
11:45 - 12:15   Pre-IVF treatment of severe tubal disease: To treat or not to treat?
                        John Petrozza, U.S.A. 
12:15 - 12:30   Discussion 
12:30 - 13:30   Lunch break 
Chair: Michel Abou Abdallah, Lebanon 
13:30 - 14:00   Pre-IVF treatment of uterine cavity defects: The do’s and the don’ts
                        Togas Tulandi, Canada 
14:00 - 14:15  Discussion
14:15 - 14:45  Pre-IVF thyroid function screening –why test, what to test and how to interpret
                       Lubna Pal, U.S.A.
 14:45 - 15:00   Discussion 
15:00 - 15:30  Coffee break 
Chair: Mohamed Aboulghar, Egypt 
15:30 - 16:00   Pre-IVF management of PCOS: How significant is the role of insulin sensitizers?
                        Lubna Pal, U.S.A. 
16:00 - 16:15  Discussion 
16:15 - 16:45  Pre-IVF management of poor response: Much ado about nothing?
                       John Petrozza, U.S.A. 
16:45 - 17:00   Discussion